Tanaz A. Kermani, MD

Tanaz A. Kermani, MD

Rheumatology
Primary Location
Santa Monica Rheumatology
2020 Santa Monica Boulevard
Suite 540
Santa Monica, California 90404
Phone
Fax
310-582-6352

About

Dr. Tanaz Kermani is the Founder and Director of the multi-disciplinary Vasculitis Program at UCLA. She grew up in Mumbai and moved to the United States in 1996 to pursue higher education. She completed her training in Internal Medicine, Rheumatology at the Mayo Clinic in Minnesota. She joined the UCLA Health's Division of Rheumatology in 2012.

She sees patients with all rheumatological diagnoses and has a special interest and expertise in vasculitis. She completed additional training in vasculitis at the Mayo Clinic, as part of a prestigious Vasculitis Clinical Research Consortium fellowship. She is an active member of the vasculitis research community, with multiple ongoing national and international collaborations with vasculitis patient advocates and medical experts. She has published several vasculitis research studies.

Dr. Kermani is deeply concerned and invested in the well-being of her patients. Her approach is to listen to her patients, and provide them with the best treatment options so she and the patients can make joint decisions concerning the best way to proceed.

Education

Medical Board Certifications

Rheumatology, American Board of Internal Medicine, 2009
Internal Medicine, American Board of Internal Medicine, 2007

Fellowship

Mayo Clinic College of Medicine and Science, 2010

Residency

Mayo Clinic College of Medicine and Science, 2007

Internship

Mayo Clinic College of Medicine and Science, 2005

Degree

New York Medical College, MD, 2004

Hospital Affiliations

Ronald Reagan UCLA Medical Center

UCLA Santa Monica Medical Center

Videos

Road Map to Wellness Webinar 4: Medications: The Good, the Bad, and the Ugly

Research

Interests

  • Giant Cell Arteritis
  • Polymyalgia Rheumatica
  • Takayasu Arteritis

Publications

Select publications below. For a complete list, link to Dr. Kermani's PubMed publications >

Large-vessel manifestations of giant cell arteritis

  1. Kermani TA, Diab S, Sreih A, Cuthbertson D, Borchin R, Carette S, Forbess LJ, Hoffman GS, Koening CL, McAlear
    CA, Monach PA, Moreland LW, Pagnoux C, Seo P, Spiera RF, Warrington KJ, Ytterberg SR, Langford CA, Khalidi NA,
    Merkel PA. Arterial Lesions in Giant Cell Arteritis: A Longitudinal Study. Seminars in Arthritis and Rheumatology.
    2019;48(4):707-713.
  2. Muratore F, Kermani TA, Crowson CS, Koster MJ, Matteson EL, Salvarani C, Warrington KJ. Large vessel dilatation
    in giant cell arteritis: a different subset of disease? Arthritis Care Res (Hoboken). 2018;70:1406-1411. PMID:
    29266882.
  3. Kermani TA, Warrington K, Crowson C, Hunder G, Ytterberg S, Gabriel S and Matteson E. Predictors of dissection
    in aortic aneurysms from giant cell arteritis: A population-based study of predictors. Journal of Clinical Rheumatology.
    2016;22(4):184-7.
  4. Muratore F, Kermani TA, Crowson CS, Green AB, Salvarani C, Matteson EL, Warrington KJ. Large-Vessel giant cell
    arteritis: a cohort study. Rheumatology (Oxford) 2015;54:463-70.
  5. Kermani TA, Crowson CS, Muratore F, Schmidt J, Matteson EL, Warrington KJ. Extra-cranial giant cell arteritis and
    Takayasu arteritis – How similar are they? Seminars Arthritis Rheum. 2015;44:724-8.
  6. Kermani TA, Warrington KJ, Crowson CS, Ytterberg SR, Hunder GG, Gabriel SE, Matteson EL. Large-Vessel
    Involvement in Giant Cell Arteritis: A Population-Based Cohort Study of the Incidence-Trends and Prognosis. Annals
    of the Rheumatic Diseases, December 2013;72:1989-1994.


Outcome measures in large-vessel vasculitis

  1. Kermani TA, Sreih AG, Cuthbertson D, Carette S, Hoffman G, Khalidi N, Koening C, Langford C, McAlear C,
    Monach P, Moreland LW, Pagnoux C, Seo P, Warrington K, Ytterberg S, Merkel P. Evaluation of Damage in Giant Cell
    Arteritis. Rheumatology (Oxford). 2018;57:322-328.
  2. Aydin SZ, Robson JC, Sreih AG, Hill C, Alibaz-Oner F, Mackie S, Beard S, Gul A, Hatemi G, Kermani TA, Mahr A,
    Meara A, Milman N, Shea B, Tomasson G, Tugwell P, Direskeneli H, Merkel PA. Update on Outcome Measure
    Development in Large-vessel Vasculitis: Report from OMERACT 2018. J Rheumtol. 2019.
  3. Sreih A, Alibaz-Oner F, Kermani TA, Aydin SZ,Cronholm, Peter, Davis T, Easley E, Gül A, Mahr A, McAlear C,
    Milman N, Robson J, Tomasson G, Direskeneli H, Merkel PA. Development of a Core Set of Outcome Measures for
    Large-Vessel Vasculitis: Report from OMERACT 2016. J Rheumatol. 2017;44:1933-1937.
  4. Kermani TA, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, Koening CL, Lanford CA, McKinnon-Maksimowicz
    K, McAlear CA, Monach PA, Seo P, Warrington KJ, Ytterberg SR, Merkel PA, Matteson EL. The Birmingham Vasculitis
    Activity Score as a measure of disease activity in giant cell arteritis. J Rheumatol. 2016;43(6);1078-84.
  5. Kermani TA, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, Koening CL, Lanford CA, McKinnon-Maksimowicz
    K, McAlear CA, Monach PA, Seo P, Warrington KJ, Ytterberg SR, Merkel PA, Matteson EL. The Birmingham Vasculitis
    Activity Score as a measure of disease activity in giant cell arteritis. J Rheumatol. 2016;43(6);1078-84.
    PMID:27036388.
  6. Kermani TA, Warrington KJ, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, Koening CL, Langford CA, McAlear
    CA, McKinnon-Maksimowicz K, Monach PA, Seo P, Merkel PA, Ytterberg SR. Disease relapses among patients with
    giant cell arteritis: A prospective, longitudinal, cohort study. J Rheumatol. 2015;42(7):1213-7.


Management guidelines

  1. Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, Mahr A, Mukhtyar C, Reynolds
    G, de Souza AWS, Brouwer E, Bukhari M, Buttgereit F, Byrne D, Cid MC, Cimmino M, Direskeneli H, Gilbert K,
    Kermani TA, Khan A, Lanyon P, Luqmani R, Mallen C, Mason JC, Matteson EL, Merkel PA, Mollan S, Neill L, Sullivan
    EO, Sandovici M, Schmidt WA, Watts R, Whitlock M, Yacyshyn E, Ytterberg S, Dasgupta B. British Society for
    Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology (Oxford). 2020 [Epub].
  2. Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, Mahr A, Mukhtyar C, Reynolds
    G, de Souza AWS, Brouwer E, Bukhari M, Buttgereit F, Byrne D, Cid MC, Cimmino M, Direskeneli H, Gilbert K,
    Kermani TA, Khan A, Lanyon P, Luqmani R, Mallen C, Mason JC, Matteson EL, Merkel PA, Mollan S, Neill L, Sullivan
    EO, Sandovici M, Schmidt WA, Watts R, Whitlock M, Yacyshyn E, Ytterberg S, Dasgupta B. British Society for
    Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology
    (Oxford). 2020 [Epub].


Invited reviews

  1. Kermani TA. Takayasu arteritis and giant cell arteritis: Are they a spectrum of the same disease. International
    Journal of Rheumatic Diseases. 2019;22(suppl 1):41-48.
  2. Unizony S and Kermani TA. IL-6 blockade and its Therapeutic Success in Giant Cell Arteritis. Journal of NeuroOphthalmology. 2018;38:551-560.
  3. Kermani TA and Warrington KJ. Prognosis and monitoring of giant cell arteritis and associated complications.
    Expert Review of Clinical Immunology. 2018;14:379-388.
  4. Kermani TA, Dasgupta B. Emerging therapies in Large-Vessel Vasculitis. Rheumatology (Oxford). 2018;57:1513-
    1524.
  5. Kermani TA, Warrington KJ. Polymyalgia rheumatica. The Lancet. 2013;5:381:63-72.

Awards

  • Top Doctors, Los Angeles Magazine, 2021
  • Top Doctors, Los Angeles Magazine, 2020
  • Top Doctors, Los Angeles Magazine, 2019
  • Fellow of the American College of Physicians (FACP) 2014
  • Vasculitis Clinical Research Consortium Fellowship, January 2010 to December 2011
  • The Philip Showalter Hench Award for Excellence in Rheumatology, May, 2010